7 active not recruiting. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 7 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow defactinib: new trials by email Literature Review of defactinib trials Research Report on defactinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients Avutometinib (VS-6766) + Defactinib (VS-6063) - Low Grade Serous Ovarian Cancer, Ovarian Cancer | Phase 2 | Active not recruiting | Verastem, Inc. | 16 | 2024-10-30 | 2025-12-17 |
| Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel - KRAS Activating Mutation, Metastatic Cancer | Phase 1 / Phase 2 | Active not recruiting | Verastem, Inc. | 40 | 2023-03-22 | 2025-09-02 |
| A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer Avutometinib (VS-6766), Defactinib - Mesonephric Gynecologic Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2023-03-15 | 2026-10-08 |
| Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients avutometinib and sotorasib, avutometinib and sotorasib and defactinib - Non Small Cell Lung Cancer, KRAS Activating Mutation | Phase 1 / Phase 2 | Active not recruiting | Verastem, Inc. | 153 | 2022-04-12 | 2026-01-12 |
| Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma Adaptive stereotactic body radiation therapy, Defactinib, Tumor biopsy - Pancreas Cancer, Cancer of the Pancreas | Phase 2 | Active not recruiting | Washington University School of Medicine | 42 | 2021-08-24 | 2026-05-08 |
| A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation avutometinib (VS-6766), avutometinib (VS-6766) and defactinib - Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | Phase 2 | Active not recruiting | Verastem, Inc. | 225 | 2020-12-21 | 2025-01-29 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
Ovarian Neoplasms (3) · Pancreatic Neoplasms (3) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Melanoma (1)
Verastem, Inc. (4) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Washington University School of Medicine (1)
United States (6) · Belgium (2) · France (2) · Spain (2) · United Kingdom (2) · Canada (1) · Guam (1) · Italy (1) · Japan (1) · Netherlands (1) · Puerto Rico (1)
MD Verastem (3) · Rachel Grisham, MD (2) · Carl DeSelm, M.D., Ph.D. (1) · Keith T Flaherty (1) · Susana Banerjee, MBBS,MA,PhD (1)
PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37598000, PMID 37934000, PMID 38493021, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40644648, PMID 40865033, PMID 41066729, PMID 42814800
R01CA248917 (1), U10CA180820 (1), U24CA196172 (1)